News

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

Iron-deficient patients on an SGLT2 inhibitor at baseline experienced greater increases in hemoglobin levels with ferric derisomaltose compared with those not taking one.

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.

In this episode, Alan Lotvin, MD, of Sequel Med Tech, joins hosts for a deep dive into the twiist automated insulin delivery system, which received clearance for people with T1D in March 2024.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.

In this interview segment, Del Rosso further explores the steps patients and clinicians should take in considering the recent Valisure report on benzene risk for skincare products with benzoyl peroxide.

A systematic review highlights the available evidence on the use of intravenous fluid in sickle cell vaso-occlusive crises and reported adverse outcomes.

FDA issued a warning for the the Impella left-sided blood pumps as it had received many reports of heart-wall tears, increasing the risk of death, hypertension, and more.

An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

Chovatiya spoke in this post-AAD interview to some of the major takeaways in psoriasis research, highlighting deucravacitinib, bimekizumab, and other therapies.

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

A new study found sleep and emotional well-being are impacted days before women get their period.

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.

In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.

In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.

In part 3 of our 5-part discussion, experts discuss the importance of screening among younger patient populations and strategies to encourage screening in patient populations susceptible to nonadherence.

In part 2 of our 5-part discussion, experts discuss challenges they face getting patients to engage in screening and how to effectively discuss screening with patients.

In part 1 of our 5-part discussion, experts discuss recent screening recommendation updates and the advent of new screening modalities.

The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.

Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.

The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target DNA stool test for detecting colorectal cancer.

Recent recommendations from the AGA may help gastroenterologists manage the rising rate of pouchitis with the aid of clinical evidence.

Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.

Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.